FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression.
Brinkmann
V
V
Transplantation Research, Novartis Pharma AG, Basel, Switzerland. volker.brinkmann@pharma.novartis.com
Chen
S
S
Feng
L
L
Pinschewer
D
D
Nikolova
Z
Z
Hof
R
R
D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D000068876:Fingolimod Hydrochloride; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D011409:Propylene Glycols / Q000494:pharmacology*; D013110:Sphingosine / Q000031:analogs & derivatives; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine